Following two weeks of disease establishment, mice (n = 10/treatment group) were randomly assigned to two groups that displayed comparable tumor burden to receive treatment with either a neutralizing anti-Grem1 antibody or an IgG control antibody. This evidence concerns the gene GREM1 and neoplasm.